N-benzyl-4-fluoro-2-nitroaniline | 887572-14-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-4-fluoro-2-nitroaniline
• CAS: 887572-14-7
• 化学式: C₁₃H₁₁FN₂O₂
• mdl: MFCD12645470
• 分子量: 246.241
• InChiKey: UYWOKZIHMJGVCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-benzyl-4-fluoro-2-nitroaniline 在 palladium on activated charcoal 盐酸 、 氢气 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 150.0~220.0 ℃ 、303.98 kPa 条件下， 反应 6.5h， 生成 2-chloro-5-fluoro-1-phenylmethyl benzimidazole
  参考文献：
  名称：

  新的2-哌嗪基苯并咪唑衍生物作为5-HT3拮抗剂。合成和药理评价。

  摘要：

  制备了一系列2-哌嗪基苯并咪唑衍生物，并将其评价为5-HT 3受体拮抗剂。通过放射性配体结合测定法评估了它们的5-HT3受体亲和力，并确定了它们在麻醉大鼠中抑制5-HT诱导的Bezold-Jarisch反射的能力。化合物7e（lerisetron，pKi = 9.2）对5-HT3受体的亲和力高于tropisetron和granisetron，而化合物7q（pKi = 7.5）对该受体的亲和力很低，表明苯并咪唑的N1原子被取代环对于亲和力和活性至关重要。还讨论了不同位置的多个取代基对苯并咪唑芳环的取代作用。建立了所研究化合物的5-HT3拮抗活性与芳香环上取代位置的强相关性。因此，尽管4-甲氧基衍生物7m显示出对5-HT 3受体的弱亲和力（pKi ＝ 6.7），但是7-甲氧基衍生物7n显示出最高的亲和力（pKi ＝ 9.4）。化合物7e和7n作为癌症化疗和放疗引起的恶心和呕吐的治疗药物，目前正在进一步研究中。

  DOI：

  10.1021/jm960442e
• 作为产物：
  描述：

  N-苄基-4-氟苯胺盐酸盐 在 盐酸 、 亚硝酸特丁酯 、 水 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 0.25h， 生成 N-benzyl-4-fluoro-2-nitroaniline
  参考文献：
  名称：

  叔丁基亚硝酸盐在温和条件下对N-烷基苯胺的区域选择性硝化

  摘要：

  据报道使用亚硝酸叔丁酯对N-烷基苯胺的区域选择性环硝化。该反应在多种底物下有效地进行，以优异的产率提供了合成上有用的N-亚硝基N-烷基硝基苯胺，可以分别使用Zn-AcOH和HCl / MeOH轻松地将其转化为N-烷基苯二胺和N-烷基硝基苯胺。

  DOI：

  10.1021/acs.joc.8b02377

文献信息

• Transcription factor modulating compounds and methods of use thereof
  申请人：Alekshun N. Michael

  公开号：US20060160799A1

  公开（公告）日：2006-07-20

  Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms.

  提供了作为抗感染剂有用的取代苯并咪唑化合物，可以降低微生物的抗药性、毒力或生长。提供了制备和使用取代苯并咪唑化合物的方法，以及其制药制剂，例如，用于降低抗生素抗性和抑制生物膜。
• Novel anti-infection agents: Small-molecule inhibitors of bacterial transcription factors
  作者：Todd E. Bowser、Victoria J. Bartlett、Mark C. Grier、Atul K. Verma、Taduesz Warchol、Stuart B. Levy、Michael N. Alekshun

  DOI：10.1016/j.bmcl.2007.07.072

  日期：2007.10

  Structure-based drug design was utilized to identify potent small-molecule inhibitors of proteins within the AraC family of bacterial transcription factors, which control virulence in medically important microbes. These agents represent a novel approach to fight infectious disease and may be less likely to promote resistance development. These compounds lack intrinsic antibacterial activity in vitro and were able to limit a bacterial infection in a mouse model of urinary tract infection. (c) 2007 Elsevier Ltd. All rights reserved.
• Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation
  作者：Onur Cil、Puay-Wah Phuan、Jung-Ho Son、Jie S. Zhu、Colton K. Ku、Niloufar Akhavan Tabib、Andrew P. Teuthorn、Loretta Ferrera、Nicholas C. Zachos、Ruxian Lin、Luis J.V. Galietta、Mark Donowitz、Mark J. Kurth、Alan S. Verkman

  DOI：10.1016/j.trsl.2016.10.003

  日期：2017.4

  Constipation is a common condition for which current treatments can have limited efficacy. By high-throughput screening, we recently identified a phenylquinoxalinone activator of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel that stimulated intestinal fluid secretion and normalized stool output in a mouse model of opioid-induced constipation. Here, we report phenylquinoxalinone structure-activity analysis, mechanism of action, animal efficacy data in acute and chronic models of constipation, and functional data in ex vivo primary cultured human enterocytes. Structure-activity analysis was done on 175 phenylquinoxalinone analogs, including 15 synthesized compounds. The most potent compound, CFTRact-J027, activated CFTR with EC50 similar to 200 nM, with patch-clamp analysis showing a linear CFTR current-voltage relationship with direct CFTR activation. CFTRact-J027 corrected reduced stool output and hydration in a mouse model of acute constipation produced by scopolamine and in a chronically constipated mouse strain (C3H/HeJ). Direct comparison with the approved prosecretory. drugs lubiprostone and linaclotide showed substantially greater intestinal fluid secretion with CFTRact-J027, as well as greater efficacy in a constipation model. As evidence to support efficacy in human constipation, CFTRact-J027 increased transepithelial fluid transport in enteroids generated from normal human small intestine. Also, CFTRact-J027 was rapidly metabolized in vitro in human hepatic microsomes, suggesting minimal systemic exposure upon oral administration. These data establish structure-activity and mechanistic data for phenylquinoxalinone CFTR activators, and support their potential efficacy in human constipation.
• Regioselective Nitration of <i>N</i>-Alkyl Anilines using <i>tert</i>-Butyl Nitrite under Mild Condition
  作者：Priyanka Chaudhary、Surabhi Gupta、Nalluchamy Muniyappan、Shahulhameed Sabiah、Jeyakumar Kandasamy

  DOI：10.1021/acs.joc.8b02377

  日期：2019.1.4

  Regioselective ring nitration of N-alkyl anilines is reported using tert-butyl nitrite. The reactions proceed efficiently with a wide range of substrates providing synthetically useful N-nitroso N-alkyl nitroanilines in excellent yields which can be easily converted into N-alkyl phenylenediamines and N-alkyl nitroanilines using Zn-AcOH and HCl/MeOH, respectively.

  据报道使用亚硝酸叔丁酯对N-烷基苯胺的区域选择性环硝化。该反应在多种底物下有效地进行，以优异的产率提供了合成上有用的N-亚硝基N-烷基硝基苯胺，可以分别使用Zn-AcOH和HCl / MeOH轻松地将其转化为N-烷基苯二胺和N-烷基硝基苯胺。
• New 2-Piperazinylbenzimidazole Derivatives as 5-HT₃ Antagonists. Synthesis and Pharmacological Evaluation
  作者：Aurelio Orjales、Ramón Mosquera、Luis Labeaga、Rosa Rodes

  DOI：10.1021/jm960442e

  日期：1997.2.1

  of 2-piperazinylbenzimidazole derivatives were prepared and evaluated as 5-HT3 receptor antagonists. Their 5-HT3 receptor affinities were evaluated by radioligand binding assays, and their abilities to inhibit the 5-HT-induced Bezold-Jarisch reflex in anesthetized rats were determined. Compound 7e (lerisetron, pKi = 9.2) exhibited higher affinity for the 5-HT3 receptor than did tropisetron and granisetron

  制备了一系列2-哌嗪基苯并咪唑衍生物，并将其评价为5-HT 3受体拮抗剂。通过放射性配体结合测定法评估了它们的5-HT3受体亲和力，并确定了它们在麻醉大鼠中抑制5-HT诱导的Bezold-Jarisch反射的能力。化合物7e（lerisetron，pKi = 9.2）对5-HT3受体的亲和力高于tropisetron和granisetron，而化合物7q（pKi = 7.5）对该受体的亲和力很低，表明苯并咪唑的N1原子被取代环对于亲和力和活性至关重要。还讨论了不同位置的多个取代基对苯并咪唑芳环的取代作用。建立了所研究化合物的5-HT3拮抗活性与芳香环上取代位置的强相关性。因此，尽管4-甲氧基衍生物7m显示出对5-HT 3受体的弱亲和力（pKi ＝ 6.7），但是7-甲氧基衍生物7n显示出最高的亲和力（pKi ＝ 9.4）。化合物7e和7n作为癌症化疗和放疗引起的恶心和呕吐的治疗药物，目前正在进一步研究中。